1/3
04:00 pm
cytk
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
12/23
07:30 am
cytk
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Low
Report
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
12/20
05:37 pm
cytk
Why Cytokinetics Stock Was a Nearly 5% Winner Today [Yahoo! Finance]
Low
Report
Why Cytokinetics Stock Was a Nearly 5% Winner Today [Yahoo! Finance]
12/20
10:22 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
12/20
12:00 am
cytk
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Medium
Report
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
12/19
07:02 am
cytk
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) [Yahoo! Finance]
Low
Report
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) [Yahoo! Finance]
12/18
10:44 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Royal Bank of Canada from $80.00 to $82.00. They now have an "outperform" rating on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Royal Bank of Canada from $80.00 to $82.00. They now have an "outperform" rating on the stock.
12/6
01:00 pm
cytk
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report? [Yahoo! Finance]
12/4
02:24 pm
cytk
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug [Yahoo! Finance]
Low
Report
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug [Yahoo! Finance]
12/3
04:00 pm
cytk
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
03:06 pm
cytk
FDA Accepts Cytokinetics' Application for Cardiovascular Drug [Yahoo! Finance]
Low
Report
FDA Accepts Cytokinetics' Application for Cardiovascular Drug [Yahoo! Finance]
12/3
07:30 am
cytk
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
Low
Report
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
12/2
04:07 pm
cytk
Cytokinetics to Participate in December Investor Conferences [Yahoo! Finance]
Low
Report
Cytokinetics to Participate in December Investor Conferences [Yahoo! Finance]
12/2
04:00 pm
cytk
Cytokinetics to Participate in December Investor Conferences
Low
Report
Cytokinetics to Participate in December Investor Conferences
12/2
10:47 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
12/2
10:24 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
12/2
07:44 am
cytk
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy [Yahoo! Finance]
Low
Report
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy [Yahoo! Finance]
12/2
07:30 am
cytk
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Medium
Report
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
11/21
08:27 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
11/20
11:12 am
cytk
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
Low
Report
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
11/20
08:07 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
11/19
08:45 am
cytk
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
Low
Report
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
11/19
05:39 am
cytk
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
Medium
Report
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
11/19
03:30 am
cytk
Bayer acquires rights to Cytokinetics' heart drug in Japan [Yahoo! Finance]
Low
Report
Bayer acquires rights to Cytokinetics' heart drug in Japan [Yahoo! Finance]
11/19
02:30 am
cytk
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Low
Report
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan